Literature DB >> 12382292

Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial.

Astrid Van Tubergen1, Annelies Boonen, Robert Landewé, Maureen Rutten-Van Mölken, Désirée Van Der Heijde, Alita Hidding, Sjef Van Der Linden.   

Abstract

OBJECTIVE: To evaluate the cost effectiveness and cost utility of a 3-week course of combined spa therapy and exercise therapy in addition to standard treatment consisting of antiinflammatory drugs and weekly group physical therapy in ankylosing spondylitis (AS) patients.
METHODS: A total of 120 Dutch outpatients with AS were randomly allocated into 3 groups of 40 patients each. Group 1 was treated in a spa resort in Bad Hofgastein, Austria; group 2 in a spa resort in Arcen, The Netherlands. The control group stayed at home and continued their usual activities and standard treatment during the intervention weeks. After the intervention, all patients followed weekly group physical therapy. The total study period was 40 weeks. Effectiveness of the intervention was assessed by functional ability using the Bath Ankylosing Spondylitis Function Index (BASFI). Utilities were measured with the EuroQoL (EQ-5D(utility)). A time-integrated summary score defined the clinical effects (BASFI-area under the curve [AUC]) and utilities (EQ-5D(utility)-AUC) over time. Both direct (health care and non-health care) and indirect costs were included. Resource utilization and absence from work were registered weekly by the patients in a diary. All costs were calculated from a societal perspective.
RESULTS: A total of 111 patients completed the diary. The between-group difference for the BASFI-AUC was 1.0 (95% confidence interval [95% CI] 0.4-1.6; P = 0.001) for group 1 versus controls, and 0.6 (95% CI 0.1-1.1; P = 0.020) for group 2 versus controls. The between-group difference for EQ-5D(utility)-AUC was 0.17 (95% CI 0.09-0.25; P < 0.001) for group 1 versus controls, and 0.08 (95% CI 0.00-0.15; P = 0.04) for group 2 versus controls. The mean total costs per patient (including costs for spa therapy) in Euros (euro;) during the study period were euro;3,023 for group 1, euro;3,240 for group 2, and euro;1,754 for the control group. The incremental cost-effectiveness ratio per unit effect gained in functional ability (0-10 scale) was euro;1,269 (95% CI 497-3,316) for group 1, and euro;2,477 (95% CI 601-12,098) for group 2. The costs per quality-adjusted life year gained were euro;7,465 (95% CI 3,294-14,686) for group 1, and euro;18,575 (95% CI 3,678-114,257) for group 2.
CONCLUSION: Combined spa-exercise therapy besides standard treatment with drugs and weekly group physical therapy is more effective and shows favorable cost-effectiveness and cost-utility ratios compared with standard treatment alone in patients with AS.

Entities:  

Mesh:

Year:  2002        PMID: 12382292     DOI: 10.1002/art.10658

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  35 in total

Review 1.  Hydrotherapy, balneotherapy, and spa treatment in pain management.

Authors:  Tamás Bender; Zeki Karagülle; Géza P Bálint; Christoph Gutenbrunner; Péter V Bálint; Shaul Sukenik
Journal:  Rheumatol Int       Date:  2004-07-15       Impact factor: 2.631

Review 2.  A proposal for a worldwide definition of health resort medicine, balneology, medical hydrology and climatology.

Authors:  Christoph Gutenbrunner; Tamas Bender; Pedro Cantista; Zeki Karagülle
Journal:  Int J Biometeorol       Date:  2010-06-09       Impact factor: 3.787

3.  [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].

Authors:  J Braun; J Zochling; E Märker-Hermann; G Stucki; H Böhm; M Rudwaleit; H Zeidler; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

Review 4.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

5.  ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

Review 6.  Balneotherapy in rheumatic diseases--an overview of novel and known aspects.

Authors:  U Lange; U Müller-Ladner; K L Schmidt
Journal:  Rheumatol Int       Date:  2005-07-12       Impact factor: 2.631

7.  How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?

Authors:  Annelies Boonen; Désirée van der Heijde; Robert Landewé; Astrid van Tubergen; Herman Mielants; Maxime Dougados; Sjef van der Linden
Journal:  Ann Rheum Dis       Date:  2007-01-09       Impact factor: 19.103

Review 8.  Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.

Authors:  Cécile Gaujoux-Viala; Bruno Fautrel
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

Review 9.  Balneotherapy in chronic inflammatory rheumatic diseases-a narrative review.

Authors:  Franco Cozzi; Luca Ciprian; Maria Carrara; Paola Galozzi; Elisabetta Zanatta; Anna Scanu; Paolo Sfriso; Leonardo Punzi
Journal:  Int J Biometeorol       Date:  2018-10-01       Impact factor: 3.787

10.  Has time come for a re-assessment of spa therapy? The NAIADE survey in Italy.

Authors:  S Coccheri; G Gasbarrini; M Valenti; G Nappi; F Di Orio
Journal:  Int J Biometeorol       Date:  2007-09-06       Impact factor: 3.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.